News
NBTX
34.00
-1.02%
-0.35
Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform
Seeking Alpha · 5h ago
Weekly Report: what happened at NBTX last week (0615-0619)?
Weekly Report · 3d ago
Qube Research & Technologies discloses net short position in Nanobiotix
PUBT · 06/16 13:41
Weekly Report: what happened at NBTX last week (0608-0612)?
Weekly Report · 06/15 09:11
Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech
Seeking Alpha · 06/12 20:58
Nanobiotix says Goldman Sachs beneficial stake rises to 7.10% of capital, 6.66% voting rights
PUBT · 06/12 15:14
WorldQuant discloses net short position in Nanobiotix
PUBT · 06/08 13:46
Weekly Report: what happened at NBTX last week (0601-0605)?
Weekly Report · 06/08 09:11
Nanobiotix Updates Share Capital and Voting Rights as of May 31, 2026
TipRanks · 06/05 20:27
Voting Rights and Shares Capital of the Company
Barchart · 06/05 15:15
Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46
Benzinga · 06/04 12:51
Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Nanobiotix (NBTX)
TipRanks · 06/04 09:10
Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029
NASDAQ · 06/03 13:23
Nanobiotix Extends Cash Runway to 2029 as Early Lung Cancer Data and Accelerated Phase 3 Plan Advance JNJ-1900
TipRanks · 06/02 22:04
Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026
Benzinga · 06/02 20:34
Nanobiotix raises about EUR 86.1 million in May share offering to fund platform development
PUBT · 06/02 20:33
Nanobiotix says Phase 2 CONVERGE study shows 85.7% response rate for JNJ-1900 in Stage 3 inoperable NSCLC
PUBT · 06/02 20:32
Nanobiotix Provides First Quarter 2026 Operational and Financial Update
Barchart · 06/02 15:30
WorldQuant discloses net short position in Nanobiotix shares
PUBT · 06/02 14:55
Nanobiotix Added to Euronext Tech Leaders Index, Boosting Investor Visibility
TipRanks · 06/02 12:54
More
Webull provides a variety of real-time NBTX stock news. You can receive the latest news about Nanobiotix S.A. through multiple platforms. This information may help you make smarter investment decisions.
About NBTX
Nanobiotix SA is a France-based nanomedicine company. The Company designs and manufactures nanoparticles that safely enhance the efficacy of radiation therapy in the treatment of cancer. It develops new tools for cancer that utilize a physical mode of action at the cellular level of the cancer cell. The Company's NanoXray technology comprises three products. Local treatment (surgery and radiotherapy) provides potential cure and gives the systemic treatment a better chance to life expectancy. NanoXray products are developed for the efficacy of radiotherapy in the tumor cell. Nanobiotix is a spin-off of the State University of New York (SUNY) at Buffalo.